Medikamentöse Therapie der Endometriose

Stefanie Burghaus, Matthias W. Beckmann
In: Die Gynäkologie · 2024 · vol. 57(3) , pp. 146–153 · doi:10.1007/s00129-024-05198-x · W4391349602
article OA: closed CC0
Limited metadata. Only one source feed has indexed this record so far — no abstract, full text, or open-access copy is available through Endo Lab. The publisher's page (linked below) is the canonical location for the actual content. If you have institutional access, use "Find at my library".
View at publisher → View on OpenAlex
⚙ AI-generated summary by claude@2026-06+body, 2026-06-07 ⓘ

Approved endometriosis treatments in Germany include dienogest, GnRH agonists, and the GnRH antagonist relugolix-CT, with oral progestins for first-line and other hormonal therapies for second-line treatment.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-07 ⓘ

The paper reviews pharmacological therapy options for endometriosis in Germany, focusing on hormonal and non-hormonal approaches and their roles across treatment lines. It summarizes evidence that oral progestins are effective for first-line treatment, while second-line options include oral estrogen–progestin combinations, alternative progestin administration forms such as a hormone coil, and GnRH agonists; it also notes that GnRH agonists have a side-effect profile linked to low compliance and that add-back therapy should be used, and that the GnRH antagonist relugolix-CT became available in November 2023 following prior medical or surgical therapy. A caveat explicitly stated in the article is that no new studies on humans or animals were conducted for this contribution. This paper is centrally about endometriosis — it provides an overview of the medical (hormonal and non-hormonal) drug therapy landscape, including newly approved relugolix-CT.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

My notes (saved in your browser only)

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (31)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK